The Management Board of Selvita S.A. with its registered office in Krakow (“Company”) hereby announces that on September 20, 2021 Company obtained information about the conclusion of the grant agreement with the National Center for Research and Development for the project implemented within the program POIR.01.01.01-00-2373/20 “Technology platform for new generations of drugs against diseases caused by coronaviruses, in particular SARS-CoV-2” (“Project”). The Project will allow the Company to expand its offer in the area of antiviral drugs development.

• Project net value: PLN 6 260 000,00;
• Financing granted: PLN 3 260 000,00;
• Project timeline: 2021-2023.

The aim of the Project is to introduce technology, which will enable to accelerate the identification of inhibitors of key proteases involved in the coronavirus replication, including that of SARS-CoV-2, by means of high throughput screening of a focused library containing innovative compounds with potential antiviral properties. The structures of the library members are unprecedented in the literature and have been designed based on the mechanism of the viral action. The compounds will be made using modern synthetic methodology, patented by the Company.

An additional advantage of the proposed service platform is its flexibility to be used for identification of a broad range of protease inhibitors. The Company assumes that as a result of the Project the process of discovering new drugs not only against SARS-CoV-2 but also against diseases caused by other viruses will shorten.

Legal basis: Art. 17 par. 1 of MAR

Representatives of the Company:
• Bogusław Sieczkowski – President of the Management Board
• Mirosława Zydroń – Management Board Member